By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on McKesson's outlook, with concerns about regulatory pressures, margin compression, and debt-funded tech spend offsetting the bullish case for a high-moat utility-like stock with stable earnings growth.
Risk: Margin compression due to debt-funded tech capex and regulatory pressures on volumes and pricing.
Opportunity: Potential EPS accretion from share buybacks if earnings growth slows.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be **downloaded here**. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The portfolio delivered strong results in 2025, with earnings growing over 15% and returns of 21%, largely driven by consistent fundamental growth rather than valuation changes. The manager highlights a diversified portfolio of high-quality, cash-generative companies with solid market positions, low investment needs, and attractive shareholder returns through dividends and buybacks. The letter notes selective portfolio shifts toward more defensive, attractively valued names while maintaining double-digit growth potential. Looking ahead, the outlook remains positive, with expectations for continued earnings growth, improving opportunities from market dispersion, and attractive valuations providing a margin of safety despite limited exposure to crowded themes like AI. In addition, please check the Fund’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Latitude Investment Management highlighted stocks like McKesson (NYSE:MCK). McKesson (NYSE:MCK) is a global healthcare company specializing in pharmaceutical distribution and supply chain solutions. The one-month return of McKesson (NYSE:MCK) was -11.46% while its shares traded between $637.00 and $999.00 over the last 52 weeks. On May 15, 2026, McKesson (NYSE:MCK) stock closed at approximately $760.57 per share, with a market capitalization of about $91.4 billion.
Latitude Investment Management stated the following regarding McKesson (NYSE:MCK) in its Q4 2025 investor letter:
"In our research process, we pay no attention to valuation. The sole focus is determining the earnings power of a business and assessing the attributes which support our outlook. However, when choosing where to allocate capital within the strategy, we pay a lot of attention to valuation. This approach occasionally leads us towards those firms and industries with strong potential but short-term headwinds. This can be a profitable approach when valuations excessively reflect the
presentconcerns, incorrectly valuing the long-term prospects. We believe this is currently the case within pockets of the healthcare sector.We started to see this opportunity in 2022, when we first invested in
McKesson (NYSE:MCK), a drug distribution company. The stocks produced returns of roughly 50% last year, driven by strong fundamental value growth of around 20% and some re-rating on top. The distribution model has proven its strong resilience, with companies having meaningfully reduced their dependence on drug pricing (by moving to fixed cost as opposed to percentage cost contracts) in the past decade. They are in effect a toll road on the US healthcare system and the opposite of economic rent-seeking businesses, creating huge value for the system while only earning a very small fraction of the industry profit pool (c.1%). While growing profits, they have also invested heavily in both technology and infrastructure, embedding their market positions at the centre of the US healthcare system."
Four leading AI models discuss this article
"MCK’s post-50% valuation leaves little margin if reimbursement reforms or litigation costs exceed current provisions."
The Latitude letter correctly flags McKesson’s shift to fixed-fee contracts and its role as essential infrastructure, which supported the roughly 20% earnings growth that drove last year’s 50% stock return. Yet the piece underplays two structural pressures: ongoing PBM and IRA-related reimbursement reforms that could compress distributor margins after 2026, and McKesson’s still-elevated exposure to opioid-related litigation reserves. With shares now at roughly 15x forward earnings after the re-rating, any shortfall in the 15%+ growth trajectory would leave little valuation cushion. The toll-road analogy holds only if volume growth and fee stability both persist.
Regulatory and legal overhangs have repeatedly failed to derail distributor earnings; McKesson has already reserved for most opioid claims and could still compound at 15%+ if specialty-drug volumes accelerate.
"MCK's fundamental earnings growth (~20%) is defensible, but the 50% return was driven 60% by valuation re-rating that may not persist, leaving current valuations vulnerable to disappointment if growth slows or macro headwinds intensify."
MCK's 50% return is real, but the article conflates two separate drivers: ~20% fundamental earnings growth (credible for a toll-road model) and ~30% re-rating (valuation expansion). The re-rating is the problem. At $760.57 with $91.4B market cap, MCK now trades at materially higher multiples than 2022. The 'fixed-cost contract' shift is genuine and defensible, but it's already priced in. The article's claim that healthcare was 'excessively discounted' in 2022 doesn't mean it still is today. One-month return of -11.46% suggests recent pullback—possibly profit-taking or margin concerns. The 'toll road' framing is seductive but incomplete: pharma pricing pressure, generic penetration, and consolidation among hospital systems all threaten MCK's volume and mix.
If MCK has truly embedded itself as indispensable infrastructure earning only 1% of industry profits, that's precisely why further re-rating is capped—the business is structurally limited in margin expansion, and current valuation may already reflect that moat.
"McKesson's transition to fixed-fee contracts has transformed it from a commodity distributor into a defensive, volume-driven utility with significant operating leverage."
McKesson (MCK) is effectively a high-moat utility masquerading as a healthcare stock. The shift to fixed-fee distribution models has successfully decoupled earnings from drug price volatility, insulating margins from political pressure. While Latitude highlights a 50% surge, the current 11.46% monthly pullback offers a tactical entry point. The 'toll road' analogy holds water: as long as GLP-1 and specialty drug volumes climb, MCK’s infrastructure is indispensable. However, the valuation re-rating is largely complete; future gains must come from organic volume growth and capital allocation efficiency rather than multiple expansion. I am looking for a stabilization above the $750 support level before confirming a continued trend.
The 'toll road' model is vulnerable to PBM (Pharmacy Benefit Manager) reform and federal pricing legislation that could compress the thin 1% margin, turning a stable utility into a regulatory target.
"McKesson's long-run earnings power could be overstated if US drug-pricing reforms and payer pressure erode margins, risking a meaningful multiple compression."
McKesson's resilience and the 'toll road' framing fit a durable-growth narrative, but the price action may reflect a re-rating rather than purely earnings-driven strength. The article largely sidesteps valuation and assumes persistent earnings power, yet US drug-pricing reforms, payer negotiation pressure, or hospital capex cycles could blunt volumes and margins. The fixed-cost contract shift helps, but rising rebates or tech investments could erode margin floors. Regulatory risk around drug pricing and reimbursement changes could compress long-run growth. The piece omits peers' valuations, debt, and capital allocation dynamics for tech upgrades, leaving upside vulnerable if expectations reset.
The 50% surge could already embed a favorable re-rating; if regulatory or payer headwinds materialize, the stock could retreat as investors reassess long-run earnings power.
"The pullback may reflect early concerns over combined regulatory and consolidation risks limiting growth below required levels."
Gemini sees the pullback as a buying opportunity, but this ignores the combined effect of PBM reforms and hospital consolidation that Claude highlighted. Together these could cap volume growth at levels below the 15% needed to justify current multiples. McKesson’s fixed-fee shift helps, yet without addressing debt-funded tech spend that ChatGPT noted, margins may face unexpected squeezes after 2026.
"Tech capex ROI failure is a nearer-term earnings risk than regulatory headwinds in 2026."
Grok conflates two separate timing issues. PBM reform and hospital consolidation are real, but they're multi-year headwinds—not 2026 cliffs. The immediate risk is margin compression from tech capex ChatGPT flagged, which could hit 2024-2025 earnings before regulatory pressures matter. If MCK's debt-funded infrastructure spend doesn't yield ROI quickly, the 15% growth narrative breaks sooner than Grok's 2026 timeline suggests. That's the near-term valuation risk.
"Share buybacks, not just operational tech ROI, are the primary mechanism supporting MCK's valuation floor amid slowing growth."
Claude, your focus on tech ROI is critical, but you're missing the capital allocation pivot. McKesson isn't just spending on tech; they are aggressively buying back shares. If earnings growth slows, the EPS accretion from buybacks acts as the true floor for the stock. The real risk isn't just margin compression from capex, but whether management exhausts their balance sheet capacity to support the stock price while the underlying volume growth from GLP-1s potentially hits a regulatory ceiling.
"Buybacks can't reliably support the stock if near-term margin pressure from capex ROI delays and regulatory headwinds erode earnings; ROIC must improve, not just the share count, for upside."
Gemini’s buyback-as-floor logic presumes stable FCF and ROIC on capex; that’s the Achilles' heel. If 2024–25 margins weaken from debt-funded tech spend and slower GLP-1 volume growth, buybacks won’t prevent multiple compression. In a world where PBM reform, pricing pressure, and hospital consolidation bite volumes, EPS growth slows even as leverage rises. The stock’s upside then hinges on ROIC improving quickly, not just buybacks propping up the multiple.
The panel is divided on McKesson's outlook, with concerns about regulatory pressures, margin compression, and debt-funded tech spend offsetting the bullish case for a high-moat utility-like stock with stable earnings growth.
Potential EPS accretion from share buybacks if earnings growth slows.
Margin compression due to debt-funded tech capex and regulatory pressures on volumes and pricing.